New drug shows promise for rare stomach disorder in japanese study

NCT ID NCT05214768

Completed Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a drug called CC-93538 (Cendakimab) in 48 Japanese adults and adolescents with eosinophilic gastroenteritis, a condition where certain white blood cells build up in the digestive tract causing pain and other symptoms. The trial was randomized and placebo-controlled, meaning some participants got the drug and others got a dummy treatment. The main goal was to see if the drug could reduce the number of these cells in gut biopsies and improve symptoms.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-93538 (Cendakimab)
What this could lead to: If successful, this could provide a new treatment option to control eosinophilic gastroenteritis, reducing inflammation and symptoms.
What could go wrong: This is a completed Phase 3 trial with only 48 participants, all Japanese. Results may not apply to other populations, and the drug may not show significant benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Digestive System Diseases digestive system disorder Eosinophilic enteropathy eosinophilic gastroenteritis gastroenteritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EOSINOPHILIC GASTROENTERITIS

Contacts and locations

Locations

Local Institution - 001

Setagaya-ku, Tokyo, 157-8535, Japan
Local Institution - 002

Osaka, 545-8586, Japan
Local Institution - 0025

Tsu, Mie-ken, 514-8507, Japan
Local Institution - 003

Yamagata, 990-9585, Japan
Local Institution - 004

Kobe, 650-0017, Japan
Local Institution - 005

Shibukawa, 377-8577, Japan
Local Institution - 006

Nagoya, 454-8509, Japan
Local Institution - 007

Bunkyo-ku, Tokyo, 113-8603, Japan
Local Institution - 008

Niigata, 951-8510, Japan
Local Institution - 009

Nishinomiya, Hyōgo, 663-8501, Japan
Local Institution - 010

Akita, 010-8543, Japan
Local Institution - 011

Maebashi, 371-8511, Japan
Local Institution - 012

Ōgaki, 503-8502, Japan
Local Institution - 013

Nagaoka, 940-2085, Japan
Local Institution - 015

Hiroshima, 734-8551, Japan
Local Institution - 016

Nagasaki, 852-8501, Japan
Local Institution - 017

Hirosaki, 036-8545, Japan
Local Institution - 018

Kagoshima, 890-8520, Japan
Local Institution - 019

Tokyo, 108-8329, Japan
Local Institution - 020

Kitakyushu, 802-8561, Japan
Local Institution - 021

Nagoya, 467-8602, Japan
Local Institution - 022

Himeji-shi, Hyōgo, 670-8560, Japan
Local Institution - 023

Sendai, Miyagi, 982-8502, Japan
Local Institution - 024

Gifu, Gifu, 5011194, Japan
Local Institution - 025

Tsu, Mie-ken, 514-8507, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.